JOHNSON + JOHNSON DL 1 (JNJ.DE) Financials
JNJ.DE Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2023-12-31 | 167.6 billion | 98.8 billion |
| 2023-09-30 | 166.1 billion | 94.8 billion |
| 2023-06-30 | 191.7 billion | 115.3 billion |
| 2023-03-31 | 196.0 billion | 125.1 billion |
JNJ.DE Free Cash Flow and Stock based compensation
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2023-12-31 | 5.8 billion | 178.0 million |
| 2023-09-30 | 6.5 billion | 296.0 million |
| 2023-06-30 | 3.1 billion | 382.0 million |
| 2023-03-31 | 2.4 billion | 306.0 million |
JNJ.DE Net Income
| Date | Net Income |
|---|---|
| 2023-12-31 | 4.0 billion |
| 2023-09-30 | 26.0 billion |
| 2023-06-30 | 5.1 billion |
| 2023-03-31 | -68.0 million |
JNJ.DE Cash and Debt
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2023-12-31 | 22.9 billion | - | - |
| 2023-09-30 | 23.5 billion | - | - |
| 2023-06-30 | 28.5 billion | - | - |
| 2023-03-31 | 24.6 billion | - | - |
JNJ.DE Shares Outstanding
JNJ.DE Expenses
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2023-12-31 | 2.1 billion | 4.5 billion | 5.8 billion | - |
| 2023-09-30 | 967.0 million | 3.4 billion | 5.4 billion | 5.4 billion |
| 2023-06-30 | 1.1 billion | 3.8 billion | 6.7 billion | - |
| 2023-03-31 | 863.0 million | 3.6 billion | 5.7 billion | 400.0 million |
JNJ.DE Cost of Revenue
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2023-12-31 | 21.4 billion | 6.8 billion |
| 2023-09-30 | 21.4 billion | 6.6 billion |
| 2023-06-30 | 25.5 billion | 8.2 billion |
| 2023-03-31 | 24.7 billion | 8.4 billion |
JNJ.DE
Price: €137.94
Dividend Yield: 0.03%
Forward Dividend Yield: 3.20%
Payout Ratio: 91.14%
Dividend Per Share: 4.42 EUR
Earnings Per Share: 4.85 EUR
P/E Ratio: 30.50
Exchange: GER
Sector: Healthcare
Industry: Drug Manufacturers - General
Volume: 2492
Market Capitalization: 335.8 billion
Average Dividend Frequency: 4
Years Paying Dividends: 25
DGR3: 1.05%
DGR5: 1.82%
DGR10: 1.82%
DGR20: 2.02%